Diagnosis and management of factor XI alloinhibitors in patients with congenital factor XI deficiency-A large single-centre experience.
bethesda assay
bleeding disorders
factor XI
factor XI deficiency
inhibitors
thrombogenomics
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
revised:
02
07
2024
received:
30
04
2024
accepted:
04
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
Factor (F) XI deficiency is an inherited bleeding disorder with increased prevalence in Ashkenazi Jews where it is mainly caused by two variants, p.Glu135* (type II, leading to a null allele) and p.Phe301Leu (type III, missense variant). Inhibitor development is rare, and only seen in severe FXI deficiency (<20 IU/dL) upon exposure to plasma-based products. We report our experience of a large cohort of patients with severe FXI deficiency, including seven patients who developed FXI alloinhibitors, their presentation, natural history and subsequent perioperative management. A single-centre retrospective database review of patients with FXI deficiency, including those who have subsequently developed inhibitors, and extraction of clinical, laboratory and genotype data, including operative management records. A total of 682 patients were identified with FXI deficiency, of whom 113 had FXI < 20 IU/dL and 42 had FXI ≤ 1 IU/dL. Factor XI inhibitors were seen in seven patients, six of whom were homozygous for the type II variant (prevalence of inhibitor with this genotype of 30%, risk of inhibitor upon plasma exposure 50%). FXI inhibitors were not seen, despite similar exposures, in patients with other genotypes. No alteration in bleeding phenotype occurred after inhibitor development and subsequent surgery was managed on 13 occasions with recombinant factor VIIa (rFVIIa), including low doses (15-30 µg/kg), with good haemostasis. The inhibitor spontaneously disappeared in four of seven patients over 1-22 years. FXI inhibitors were only observed in severe FXI deficient patients homozygous for p.Glu135* (null allele) upon plasma or FXI concentrate exposure, with a 30% prevalence. The bleeding phenotype was not altered and inhibitors may disappear with time. Adequate haemostasis in the perioperative setting is achievable with low doses of rFVIIa.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom haemophilia centre doctors’ organization guideline on behalf of the British committee for standards in haematology. Br J Haematol. 2014;167(3):304‐326.
Gomez K, Bolton‐Maggs P. Factor XI deficiency. Haemophilia. 2008;14(6):1183‐1189.
A UKHCDO Annual Report 2022 & Bleeding Disorder Statistics for the Financial Year 2021/2011. Machester; 2022. https://www.ukhcdo.org/wp‐content/uploads/2022/12/UKHCDO‐Annual‐Report‐2022‐2021‐22‐Data.pdf
Salomon O. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003;101(12):4783‐4788.
Ling G, Kagdi H, Subel B, et al. Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single‐centre experience of 19 years. Haemophilia. 2016;22(3):411‐418.
Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI‐deficient patients with inhibitor antibodies. Thromb Haemost. 2009;102(3):487‐492.
Riddell A, Abdul‐Kadir R, Pollard D, et al. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost. 2011;106(3):521‐527.
Bern MM, Sahud M, Zhukov O, et al. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia. 2005;11(1):20‐25.
Bauduer F, de Raucourt E, Boyer‐Neumann C, et al. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3‐year postmarketing study. Haemophilia. 2015;21(4):481‐489.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405‐424.
Murray NP, Ilabaca J, Guzman E, et al. Management of mild congenital deficiency of factor XI with a factor XI inhibitor in pregnancy: a clinical case. Hematol Transfus Cell Ther. 2022;44(3):444‐446.
Asakai R, Chung DW, Davie EW, et al. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325(3):153‐158.
Shpilberg O, Peretz H, Zivelin A, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood. 1995;85(2):429‐432.
Zucker M, Zivelin A, Teitel J, et al. Induction of an inhibitor antibody to factor XI in a patient with severe inherited factor XI deficiency by Rh immune globulin. Blood. 2008;111(3):1306‐1308.
Chitlur MB, Lusher JM. Factor IX inhibitors in hemophilia B. Textbook of Hemophilia. Wiley; 2014:103‐106.
Vercellotti GM, Mosher DF. Acquired factor XI deficiency in systemic lupus erythematosus. Thromb Haemostasis. 1982;48(3):250‐252.
Goodrick MJ, Prentice AG, Copplestone JA, et al. Acquired factor XI inhibitor in chronic lymphocytic leukaemia. J Clin Pathol. 1992;45.
Mi J, Liu C, Huang X, et al. Acquired factor XI inhibitor with immune system disorder. Med Case Rep Study Protoc. 2021;2(4):e0079.
Yankol Y, Mecit N, Kanmaz T, et al. Acquired factor XI deficiency: a rare complication after liver transplantation. Transplant Proc. 2015;47(1):179‐181.
Mcmanus MP, Frantz C, Gailani D. Acquired factor XI deficiency in a child with membranoproliferative glomerulonephritis. Pediatr Blood Cancer. 2012;59(1):173‐175.
Andreani G, Uscello L, Montaruli B, et al. Acquired factor XI deficiency during SARS‐CoV‐2 infection: not only thrombosis. TH Open. 2020;04(03):e233‐235.
Bortoli R, Monticielo OA, Chakr RM, et al. Acquired factor XI inhibitor in systemic lupus erythematosus‐case report and literature review. Semin Arthritis Rheum. 2009;39(1):61‐65.
Nakajima R, Togo A, Kanno Y, et al. Acquired factor XI deficiency with lupus anticoagulant in a pregnant woman diagnosed by the eruptions and pain in fingers. Case Rep Obstet Gynecol. 2020;2020:8854676.
Harada N, Makuuchi Y, Kuno M, et al. Intramural esophageal hematoma precipitated by acquired factor XI deficiency in a patient with relapsed T cell prolymphocytic leukemia after allogeneic hematopoietic cell transplantation. Ann Hematol. 2022;101:2567‐2569.
Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol. 2004;127(4):379‐391.
Collins PW, Chalmers E, Hart D, et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol. 2013;162(6):758‐773.
Connelly NR, Brull SJ. Anesthetic management of a patient with factor XI deficiency and factor XI inhibitor undergoing a cesarean section. Anesth Analg. 1993;76(6):1365‐1366.
Teruya J, Styler M. Management of factor XI inhibitor for cardiac intervention: successful treatment with immunosuppressive therapy and plasma exchange. Haemophilia. 2000;6(3):158‐161.
Wool GD, Treml A, Miller JL. Acquired factor XI deficiency and therapeutic plasma exchange. J Clin Apher. 2018;33(3):427‐430.
Vazzana N, Scarti L, Beltrame C, et al. Acquired factor XI inhibitor presenting as spontaneous bilateral subdural hematoma in an elderly patient. Case Rep Hematol. 2014;2014:1‐4.
Ginsberg SS, Clyne LP, McPhedran P, et al. Successful childbirth by a patient with congenital factor XI deficiency and an acquired inhibitor. Br J Haematol. 1993;84(1):172‐174.
Mungee S, Lapin R, Cavusoglu E, et al. Percutaneous coronary intervention in a patient with congenital factor XI deficiency and acquired inhibitor. Cardiology. 2006;107(1):69‐72.
Lawler P, White B, Pye S, et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia. 2002;8(2):145‐148.
Billon S, Le Niger C, Escoffre‐Barbe M, et al. The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis. 2001;12(7):551‐553.